Current Clinical Trials
Biogen Idec EXTEND 205MS303 Phase III
A Multicenter, Open-label, Extension Study to Evaluate the Long-Term Safety and Efficacy of BIIB019, Daclizumab High Yield Process (DAC HYP),Monotherapy in Subjects With Multiple Sclerosis Who Have Completed Study 205MS301
Biogen Idec Escalate 101MS409 Phase IV
A Phase 4 Multicenter, Open-label, Single Arm Study to Evaluate Switching from BRACET/Gilenya to Natalizumab in Subjects with Relapsinf Forms of Multiple Sclerosis (MS)
Biogen Idec Respond 109MS404 Phase IV
A Multicenter, Open-Label, 12 Month Observational Study Evaluating the Clinical Effectiveness and Impact on Patient-Reported Outcomes of Oral Tecfidera (dimethyl fumarate) Delayed-Relase Capsules in Patients With Relapsing Forms of Multiple Sclerosis After Suboptimal Response to Glatiramer Acetate
Biogen Idec Reveal 101MS408 Phase IV
A Multicenter, Randomized, Open-label Study to Assess the Impact of Natalizumab versus Fingolimod on Central Nervous System Tissue Damage and Recovery in Active Relapsing-Remitting Multiple Sclerosis Subjects
Biogen STRATIFY-2 101JC402 Phase IV
JCV Antibody Program in Patients with Relapsing Multiple Sclerosis Receiving or Considering Treatment with Tysabri: STRATIFY-2
Biogen Idec TYGRIS Registry NCT00477113 Phase IV
Safety Observational Program Designed to Obtain Long-Term Safety Data in Patients Treated with Tysabri in a Clinical Practice Setting
Chugai NMO Study SA-309-jG Phase III
A Multicenter, Randomized, Double-blind, Placebo-controlled, Phase 3 Study to evaluate the Efficacy and safety of SA237 as Monotherapy in Patients with Neuromyelitis Optica (NMO) and Neuromyelitis Optica Spectrum Disorder (NMOSD)
EMDSerono Human Factors Study
A Human Factors Supplemental Summative Usability Test of the Investigational REbif Electronic Autoinjector (EAI) in Subjects With Relapsing Multiple Sclerosis (RMS) and Healthcare Providers
EMDSerono Pathway EMR200575-001 Phase II
A Phase II, Randomized, Multi-center, Parallel-group, Rater-blinded Study to Evaluate the Efficacy, Safety and Tolerability of 0.5mg, 3mg, 10mg and 20mg Plovamer Acetate Doses Compared to Copaxone in Patients with Relapsing Remitting Multiple Sclerosis
Genzyme CAMMS03049 Phase III
An Extension Protocol For Multiple Sclerosis Patients Who Participated in Genzyme-Sponsored Studies of Alemtuzumab
Novartis ASSESS
A 12 month, randomized, rater- and dose-blinded study to compare the efficacy and safety of fingolimod 0.25 mg and 0.5 mg administered orally once daily with glatiramer acetate 20 mg administered subcutaneously once daily in patients with relapsing-remitting multiple sclerosis
Novartis PREFERMS Fingolimod/FTY720
A 12 month, Prospective, Randomized, active-controlled, open-label study to Evaluate the patient retention of Fingolimod vs approved first-line disease modifying therapies in adults who are in Early stages of treatment for Relapsing Remitting Multiple Sclerosis
ONO Pharmaceuticals ONO-4641POU007 Phase II
A 26-Week Safety and Efficacy Extension Study of ONO-4641 in Patients with Relapsing-Remitting Multiple Sclerosis
Opexa Therapeutics T-Celna
A Phase 2 Double-Blind, Placebo Controlled Multi-Center Study to Evaluate the Efficacy and Safety of Tcelna in Subjects with Secondary Progressive Multiple Sclerosis
Roche OPERA II Ocrelizumab Protocol WA21093 Phase III
A Multi-Center, Double-Blind (with respect to Ocrelizumab dose) and Rater-Blind (Versus Comparitor), Parallel-Group Study To Evaluate the Efficacy and Safety of Two Doses of Ocrelizumab in Comparison to Iterferon Beta-1a(Rebif) in Patients
If you are interested in participating in one of our clinical trials, please call the Clinical Research Center at CTNC to obtain more information.
A Multicenter, Open-label, Extension Study to Evaluate the Long-Term Safety and Efficacy of BIIB019, Daclizumab High Yield Process (DAC HYP),Monotherapy in Subjects With Multiple Sclerosis Who Have Completed Study 205MS301
Biogen Idec Escalate 101MS409 Phase IV
A Phase 4 Multicenter, Open-label, Single Arm Study to Evaluate Switching from BRACET/Gilenya to Natalizumab in Subjects with Relapsinf Forms of Multiple Sclerosis (MS)
Biogen Idec Respond 109MS404 Phase IV
A Multicenter, Open-Label, 12 Month Observational Study Evaluating the Clinical Effectiveness and Impact on Patient-Reported Outcomes of Oral Tecfidera (dimethyl fumarate) Delayed-Relase Capsules in Patients With Relapsing Forms of Multiple Sclerosis After Suboptimal Response to Glatiramer Acetate
Biogen Idec Reveal 101MS408 Phase IV
A Multicenter, Randomized, Open-label Study to Assess the Impact of Natalizumab versus Fingolimod on Central Nervous System Tissue Damage and Recovery in Active Relapsing-Remitting Multiple Sclerosis Subjects
Biogen STRATIFY-2 101JC402 Phase IV
JCV Antibody Program in Patients with Relapsing Multiple Sclerosis Receiving or Considering Treatment with Tysabri: STRATIFY-2
Biogen Idec TYGRIS Registry NCT00477113 Phase IV
Safety Observational Program Designed to Obtain Long-Term Safety Data in Patients Treated with Tysabri in a Clinical Practice Setting
Chugai NMO Study SA-309-jG Phase III
A Multicenter, Randomized, Double-blind, Placebo-controlled, Phase 3 Study to evaluate the Efficacy and safety of SA237 as Monotherapy in Patients with Neuromyelitis Optica (NMO) and Neuromyelitis Optica Spectrum Disorder (NMOSD)
EMDSerono Human Factors Study
A Human Factors Supplemental Summative Usability Test of the Investigational REbif Electronic Autoinjector (EAI) in Subjects With Relapsing Multiple Sclerosis (RMS) and Healthcare Providers
EMDSerono Pathway EMR200575-001 Phase II
A Phase II, Randomized, Multi-center, Parallel-group, Rater-blinded Study to Evaluate the Efficacy, Safety and Tolerability of 0.5mg, 3mg, 10mg and 20mg Plovamer Acetate Doses Compared to Copaxone in Patients with Relapsing Remitting Multiple Sclerosis
Genzyme CAMMS03049 Phase III
An Extension Protocol For Multiple Sclerosis Patients Who Participated in Genzyme-Sponsored Studies of Alemtuzumab
Novartis ASSESS
A 12 month, randomized, rater- and dose-blinded study to compare the efficacy and safety of fingolimod 0.25 mg and 0.5 mg administered orally once daily with glatiramer acetate 20 mg administered subcutaneously once daily in patients with relapsing-remitting multiple sclerosis
Novartis PREFERMS Fingolimod/FTY720
A 12 month, Prospective, Randomized, active-controlled, open-label study to Evaluate the patient retention of Fingolimod vs approved first-line disease modifying therapies in adults who are in Early stages of treatment for Relapsing Remitting Multiple Sclerosis
ONO Pharmaceuticals ONO-4641POU007 Phase II
A 26-Week Safety and Efficacy Extension Study of ONO-4641 in Patients with Relapsing-Remitting Multiple Sclerosis
Opexa Therapeutics T-Celna
A Phase 2 Double-Blind, Placebo Controlled Multi-Center Study to Evaluate the Efficacy and Safety of Tcelna in Subjects with Secondary Progressive Multiple Sclerosis
Roche OPERA II Ocrelizumab Protocol WA21093 Phase III
A Multi-Center, Double-Blind (with respect to Ocrelizumab dose) and Rater-Blind (Versus Comparitor), Parallel-Group Study To Evaluate the Efficacy and Safety of Two Doses of Ocrelizumab in Comparison to Iterferon Beta-1a(Rebif) in Patients
If you are interested in participating in one of our clinical trials, please call the Clinical Research Center at CTNC to obtain more information.
Schedule your appointment today.
- call us at -
512-218-1222
- or -
- call us at -
512-218-1222
- or -
